Champions Oncology, Inc. · NASDAQ:CSBR
Champions Oncology — Investor Presentation (May 2016)
22 slides from Champions Oncology's investor presentation, May 18, 2016
Slide 1: Investor Presentation May 2016
1 Investor Presentation May 2016
Slide 2: Notice of Forward Looking Statements
2 Notice of Forward Looking Statements Thispresentationcontainscertain“forward-lookingstatements,”whichincludeinformationrelatingtofutureevents, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. These forward-looking statement
Slide 3: Offering Summary
3 Offering Summary 3 Note: Market data as of 5/11/2016 Issuer Champions Oncology, Inc. Securities Common Shares (registered) Useof Proceeds R&D to grow TumorGraft platform, working capital and general corporate purposes Underwriter NationalSecuritiesCorporation Anticipated Pricing Early June 2016 Ti
Slide 4: Why Invest in Champions Oncology?
4 Why Invest in Champions Oncology? Innovation Innovative technology platform serving the pharmaceutical industry Market Size Large and growing market size Experience Experienced management team Progress 5 years of revenue growth and scientific progress
Slide 5: Our Senior Management Team
5 Our Senior Management Team Joel Ackerman 15 years at Warburg Pincus investing in healthcare Board of Directors: Coventry Healthcare, Kindred Healthcare CEO David Sidransky, MD Johns Hopkins University, Professor and Director Head and Neck Cancer Research; Former Vice Chairman, Imclone Systems Chai
Slide 6: The Problem with Oncology Drugs
6 The Problem with Oncology Drugs Despite Advances, Response Rates Remain Low Skyrocketing R&D Costs Failure Rates Remain High Unsustainable Increases in Oncology Drug Costs $1.2 billion average capital outlay per approved biopharmaceutical Average monthly cost of more than $11,000 for new cancer dr
Slide 7: Champions' Platform Addresses the Challenges Created by Oncology Clinical Trials
7 Champions’ Platform Addresses the Challenges Created by Oncology Clinical Trials Cost per patient: > $100,000 Time to Complete: 8 years CHALLENGE OF ONCOLOCY CLINICAL TRIALS Clinical Trial Simulation Platform CHAMPIONS SOLUTION Chance of Success: 7%
Slide 8: Simulating Patient Response to Oncology Drugs with Patient Derived XenoGrafts (PDX)
8 ? Simulating Patient Response to Oncology Drugs with Patient Derived XenoGrafts (PDX) Mice are dosed with different anti-tumor therapies Patient tumor is implanted in immune-compromised mice The effect of each therapy on tumor growth is measured ? ? ? Patient Implant Treatment Measurement
Slide 9: The Predictive Power of PDX
9 The Predictive Power of PDX A growing body of evidence demonstrates positive predictive value for Champions TumorGraft® PDX models. Clinical Accuracy Measures Result 95% Cl Positive Predictive Value (PPV) 87%(80/92) 77% -93% Negative Predictive Value (NPV) 94%(32/34) 79% -99% Source: 126 TumorGraf
Slide 10: Champions TumorGraft is an Immortalized Model of an Individual Patient for Predicting Response
10 Champions TumorGraft is an Immortalized Model of an Individual Patient for Predicting Response Patient Data Perpetual Tissue Stock Genomic Data
Slide 11: The Champions TumorGraft Platform Today
11 The Champions TumorGraft® Platform Today 700 PDX models in our tumor bank that reflect characteristics of patients who enroll in clinical trials (late stage, pretreated and metastic)
Slide 12: The Value of Patient Derived Xenografts
12 The Value of Patient Derived Xenografts Economics 90%+ lower costs than a human clinical trial PDX Repeatability Same patient can be run with multiple drugs for head-to-head comparisons Speed 6 months to study completion versus 2-3 years for human trial Predictability 90%+ accuracy in predicting
Slide 13: Champions Has Built a Successful Core Business
13 Champions Has Built a Successful Core Business 450 Studies Completed Ranging in size from $25,000 to more than $1 million 100 Customers Served Including 16 of the top 20 pharma companies and 84 other pharma and biotech companies 34% Revenue Growth 5 year cumulative annual growth rate in core busi
Slide 14: Three Strategies for Accelerating Revenue Growth
14 Three Strategies for Accelerating Revenue Growth Immune Oncology Grow the Platform Innovative Study Designs
Slide 15: Champions is Employing Novel Approaches to Grow the Breadth and Depth of the TumorBank
15 Champions is Employing Novel Approaches to Grow the Breadth and Depth of the TumorBank Deepening the Bank Research Custom Model Development Patients Broadening the Bank
Slide 16: Champions ImmunoGraft Development
16 Champions ImmunoGraft ™ Development A novel platform using Champions TumorGraft platform in humanized mice Proliferating human immune cells measured Screening against immuno-oncology agents Murine immune system eradicated and human immune system Implanted Tumors from patients or banked tumors imp
Slide 17: Innovative Study Designs Enable Larger Studies
17 Pre-clinical Phase 1 Phase 2 Phase 3 $0 $30 $60 $90 $120 $150 Cost Per Drug by Phase ($ millions) $150 $488 $690 $0 $500 $1,000 $1,500 Total Available Market Size 1 ($ millions) 1 Company estimates Innovative Study Designs Enable Larger Studies Recent bookings will drive accelerated revenue growt
Slide 18: Champions Operational Capabilities
18 Champions Operational Capabilities Corporate Headquarters Hackensack, NJ Approximately 70 FTEs 20MDs or PhDs Primary Lab & Vivarium Baltimore, MD Johns Hopkins Science + Technology Center AAALAC accredited ISO 9001:2008 certified CLIA certified Facility Breakdown 8,000 square feet 8 procedure roo
Slide 19: Historical and Future Financial Results
19 Historical and Future Financial Results Current Financial Results x LTM Revenue: $11.6 mm x 5 year core revenue growth 1 : 34% x Cash flow positive before R&D expenditure 2 x Quarterly cash burn 2 : $860,000 Fiscal Year 2017 Financial Projections x Acceleratingrevenue growth x Cash flow positive
Slide 20: Upcoming Milestones
20 Upcoming Milestones Strategic Commercial Partnerships Sponsored R&D Collaborations New Product Introductions
Slide 21: Shareholder Composition
21 Shares Common Shares Common Institutional and Corporate Investors (1) Held Stock Insiders (1) Held Stock Battery Ventures 1,958,862 36.3% Battery Ventures 1,958,862 54.7% New Enterprise Associates 1,562,500 29.0% Sidransky, David 891,665 24.9% Par Capital Management, Inc. 833,333 15.5% Morris, Ro
Slide 22: Champions Oncology Contact
22 CHAMPIONS ONCOLOGY One University Plaza | Suite 307 Hackensack, NJ OUR EMAIL sforeman@championsoncology.com OUR PHONE 201.808.8400 OUR WEBSITE www.championsoncology.com
Champions Oncology — Investor Presentation (May 2016) on 6ix